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Background: Metabolic syndrome (MS) is associated with increased risks of diabetes and atherosclerotic
cardiovascular disease. However, data on the impact of MS and its individual components on subclinical
atherosclerosis (SCA) according to diabetes status are scarce.
Methods: Surrogate markers of SCA, brachial–ankle pulse wave velocity (baPWV), and carotid intima–medial
thickness (IMT) and plaque were assessed in 2,560 subjects (60 ± 8 years, 33% men) who participated in baseline
health examinations for a community-based cohort study.
Results: The participants included 2,149 non-diabetics (84%) and 411 diabetics (16%); 667 non-diabetics (31%) and
285 diabetics (69%) had MS, respectively. Diabetics had significantly higher baPWV and carotid IMT, and more
plaques than non-diabetics (p < 0.001, respectively). Individuals with MS had significantly higher baPWV and carotid
IMT than those without MS only among non-diabetics (p < 0.001, respectively). Among MS components, increased
blood pressure was significantly associated with the exacerbation of all SCA markers in non-diabetics. The number of
MS components was significantly correlated with both baPWV and carotid IMT in non-diabetics (baPWV: r = 0.302,
p < 0.001; carotid IMT: r = 0.217, p < 0.001). Multiple regression showed both MS and diabetes were significantly
associated with baPWV (p < 0.001, respectively), carotid IMT (MS: p < 0.001; diabetes: p = 0.005), and the presence of
plaque (MS: p = 0.041; diabetes: p = 0.002).
Conclusions: MS has an incremental impact on SCA in conditions without diabetes. The identification of MS and its
individual components is more important for the risk stratification of CVD in non-diabetic individuals.
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Metabolic syndrome (MS) represents a clustering of sev-
eral cardiovascular (CV) risk factors including abdom-
inal obesity, impaired glucose intolerance, dyslipidemia,
and hypertension, with insulin resistance as a major
characteristic [1,2]. It was recently estimated that MS is
common, affecting 24% of adults in the US and 11–19%
in Korea [3,4]. MS is associated with the development of
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reproduction in any medium, provided the orMS has been promoted as a means of identifying the
risk of diabetes development. A number of different defi-
nitions of MS include diabetes as part of the diagnostic
criteria of MS. Recently, it has been strongly re-
commended that conditions with established diabetes or
cardiovascular disease (CVD) should be excluded from
the definition of MS, because MS is a pre-morbid condi-
tion rather than a clinical diagnosis [7]. However, there
is a paucity of data supporting this recommendation,
especially regarding atherosclerosis. In addition, the
effects of MS and its individual components on subclin-
ical atherosclerosis (SCA) according to diabetes status
are unknown.d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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carotid artery can be measured noninvasively using
high-resolution B-mode ultrasound. Brachial–ankle
pulse wave velocity (baPWV) is used as a reproducible
index of arterial elasticity and stiffness. Both increased
baPWV and thickened IMT of the carotid artery are im-
portant surrogate markers of SCA that represent an in-
creased risk of CV events [8,9]. The present study
investigated the effects of MS and its components on
SCA according to diabetes status in a sample of 2,560
adults who participated in baseline health examinations
for a community-based cohort study.
Methods
Subjects
This is a cross-sectional investigation analyzing baseline
data collected for a prospective cohort study. We used
the data of 2,560 subjects who participated in baseline
health examinations for a community-based cohort
study in the Seoul area between April 2010 and Novem-
ber 2012. Subjects with a clinical history of CVD, cere-
brovascular disease, neurological abnormalities, cerebral
hemorrhage, or malignancy were excluded. The study
protocol was approved by the local ethics committee of
our institution, and informed consent for the procedure
was obtained from each individual.
Measurement of biochemical and clinical parameters
All blood samples were obtained after 8 hours of fasting
and analyzed for glucose, triglycerides, high-density lipo-
protein (HDL) cholesterol, and low-density lipoprotein
(LDL) cholesterol. Height, weight, and waist circumfer-
ence were measured while subjects wore light clothing
and no shoes. Waist circumference was measured at the
midpoint between the lower border of the rib cage and
iliac crest. Body mass index (BMI) was calculated as
weight (kg) ÷ height (m2). MS was defined as when 3 or
more of the following were present: (a) abdominal obesity
based on waist circumference ≥ 90 cm in males or ≥ 80 cm
in females; (b) HDL cholesterol < 40 mg/dL in males or
<50 mg/dL in females; (c) fasting triglycerides ≥ 150 mg/
dL; (d) blood pressure ≥ 130 mmHg systolic or ≥ 85 mmHg
diastolic, or on treatment; and (e) impaired fasting
glucose, defined as fasting glucose ≥ 100 mg/dL, based on
the American Heart Association/National Heart, Lung,
and Blood Institute (AHA/NHLBI) definition [2]. Diabetes
was defined as either fasting glucose ≥ 126 mg/dL, a refer-
ral diagnosis of diabetes, or antidiabetic treatment.
Measurement of baPWV
All subjects abstained from caffeine-containing food or
beverages for at least 45 minutes prior to baPWV meas-
urement. After a subject had been resting in the supine
position for at least 5 minutes in a quiet room, bloodpressure and baPWV were measured using an auto-
mated waveform analyzer (Colin VP-2000, Colin Medical
Instruments Corp., Komaki, Japan). Pneumatic cuffs
were wrapped around both upper arms and ankles and
connected to a plethysmographic sensor to determine
the volume pulse waveform; the higher value of blood
pressure was used for analysis. The highest value of
baPWV measured on either side of each patient was
used for analysis.
Measurement of carotid IMT and plaques
Carotid IMT was measured using high-resolution B-
mode ultrasonography (Acuson X300, Siemens, USA)
with a transducer frequency of 13–15 MHz. Computer-
assisted acquisition, processing, B-mode images storage,
and calculation of IMT were performed using the Syngo
Arterial Health Package (Siemens, USA). Automatic
measurements from both common carotid arteries were
made at the far wall of the 1-cm segment distal to the
carotid bulbs. The mean value of carotid IMT was used
for analysis. All carotid IMT measurements were taken
at sites free of any discrete plaques. Carotid plaque was
defined as the presence of focal wall thickening at least
50% greater than that of the surrounding vessel wall or
as a focal region with a carotid IMT greater than
1.5 mm, protruding into the lumen and distinct from
the neighboring boundary [10,11].
Statistical analysis
Clinical and biochemical characteristics are shown
according to the presence of diabetes and MS. Values
are expressed as mean ± SD. Continuous variables were
compared using Student’s t-test, and categorical variables
were compared using the χ2 test. Differences in baPWV
and carotid IMT with respect to each MS component
were tested using ANCOVA separately for individuals
with and without diabetes. Correlational analysis be-
tween the number of MS components, and baPWV and
carotid IMT according to diabetes status was performed
using Pearson’s correlation test. Multiple regression
analysis was used to evaluate the significance of
confounding risk factors for baPWV and carotid IMT.
Multiple logistic regression analysis was used to evaluate
the significant risk factors for carotid plaques. SPSS ver-
sion 18 (SPSS Inc., Chicago, IL, USA) was used for all
statistical analyses. All statistical tests were 2-tailed, and
p < 0.05 was considered significant.
Results
Clinical characteristics
The clinical characteristics of the 2,560 participants (60 ±
8 years, 33% men) in this study are shown in Table 1. This
study included 2,149 non-diabetics (84%) and 411 dia-
betics (16%). Both non-diabetics and diabetics were
Table 1 Clinical characteristics of the study subjects
Characteristics No diabetes p Type 2 diabetes p
Total
(n = 2149)
No metabolic
syndrome
(n = 1482)
Metabolic
syndrome
(n = 667)
Total
(n = 411)
No metabolic
syndrome
(n = 126)
Metabolic
syndrome
(n = 285)
Age (years) 60 ± 8 59 ± 8 62 ± 7 <0.001 63 ± 8 * 63 ± 7 63 ± 8 0.354
Men, n (%) 638 (30%) 428 (29%) 210 (32%) 0.222 204 (50%) * 68 (54%) 136 (48%) 0.243
Waist circumference (cm) 83 ± 8 81 ± 8 88 ± 7 <0.001 88 ± 8 * 81 ± 7 90 ± 8 <0.001
Body mass index (kg/m2) 24.7 ± 2.9 24.0 ± 2.7 26.3 ± 2.8 <0.001 25.5 ± 3.2 * 23.3 ± 2.2 26.5 ± 3.1 <0.001
Smoking, n (%) 521 (24%) 336 (23) 185 (28%) 0.011 174 (42%) * 52 (41%) 122 (43%) 0.771
Heart rate (bpm) 66 ± 9 66 ± 9 67 ± 10 0.080 70 ± 10 * 69 ± 10 70 ± 10 0.304
SBP (mmHg) 122 ± 15 119 ± 14 128 ± 15 <0.001 128 ± 15 * 124 ± 15 130 ± 15 <0.001
DBP (mmHg) 74 ± 10 72 ± 9 77 ± 10 <0.001 76 ± 10 * 73 ± 9 77 ± 10 <0.001
Antihypertensive drugs, n (%) 843 (39%) 416 (28%) 427 (64%) <0.001 251 (61%) * 46 (37%) 205 (72%) <0.001
Total cholesterol (mg/dL) 202 ± 35 202 ± 35 200 ± 35 0.379 187 ± 39 * 185 ± 34 187 ± 41 0.493
Triglyceride (mg/dL) 126 ± 67 105 ± 47 173 ± 80 <0.001 144 ± 85 * 96 ± 34 165 ± 92 <0.001
HDL cholesterol (mg/dL) 55 ± 15 59 ± 14 46 ± 12 <0.001 50 ± 13 * 57 ± 11 47 ± 13 <0.001
LDL cholesterol (mg/dL) 124 ± 32 124 ± 32 124 ± 33 0.929 110 ± 35 * 109 ± 31 111 ± 36 0.524
Lipid lowering drugs, n (%) 571 (27%) 384 (26%) 187 (28%) 0.302 149 (36%) * 45 (36%) 104 (37%) 0.880
Creatinine (mg/dL) 0.78 ± 0.18 0.78 ± 0.18 0.79 ± 0.18 0.029 0.82 ± 0.22 * 0.81 ± 0.24 0.83 ± 0.21 0.464
FBS (mg/dL) 95 ± 9 93 ± 8 100 ± 10 <0.001 132 ± 33 * 128 ± 36 133 ± 32 0.187
Antidiabetic treatments, n (%) - - - - 347 (84%) * 112 (89%) 235 (83%) 0.097
Duration of diabetes (months) - - - - 117 ± 91 131 ± 102 110 ± 85 0.058
baPWV (cm/s) 1476 ± 250 1438 ± 230 1562 ± 271 <0.001 1641 ± 284 * 1609 ± 273 1655 ± 288 0.133
Carotid IMT (mm) 0.76 ± 0.20 0.73 ± 0.19 0.81 ± 0.22 <0.001 0.84 ± 0.26 * 0.83 ± 0.25 0.84 ± 0.26 0.773
Carotid plaques, n (%) 453 (21%) 273 (18%) 180 (27%) <0.001 148 (36%) * 51 (41%) 97 (34%) 0.222
Data are expressed as n (%) or mean ± SD. baPWV, brachial–ankle pulse wave velocity; DBP, diastolic blood pressure; FBS, fasting blood sugar; HDL, high-density
lipoprotein; IMT, intima–medial thickness; LDL, low-density lipoprotein; SBP, systolic blood pressure. *p < 0.001 vs. no diabetes.
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MS. The prevalence of AHA/NHLBI-defined MS in
the present study was 40%; 667 non-diabetics (31%)
and 285 diabetics (69%) were classified as having MS,
respectively.Differences in SCA parameters according to the presence
of MS and diabetes
The mean baPWV, carotid IMT, and prevalence of ca-
rotid plaques were significantly higher in diabetics than
non-diabetics (baPWV: 1641 ± 284 vs. 1476 ± 250 cm/s,
p < 0.001; carotid IMT: 0.84 ± 0.26 vs. 0.76 ± 0.20 mm,
p < 0.001; carotid plaques: 36vs.21%, p < 0.001). Sub-
jects with MS had significantly higher baPWV and ca-
rotid IMT as well as more plaques than those without
MS among only non-diabetics (baPWV: 1562 ± 271 vs.
1438 ± 230 cm/s, p < 0.001; carotid IMT: 0.81 ± 0.22
vs. 0.73 ± 0.19 mm, p < 0.001; carotid plaques: 27 vs.
18%, p < 0.001) (Table 1 and Figure 1). Data related to
comparison of SCA parameters between 4 groups are
provided in Additional file 1: Table S1.Impact of individual MS component on SCA parameters
according to diabetes status
After adjusting for age, gender, smoking status, LDL,
and BMI, MS components including increased blood
pressure, triglycerides and fasting glucose as well as de-
creased HDL were significantly associated with higher
baPWV in non-diabetics. MS components including
increased waist circumference and blood pressure, and
decreased HDL were significantly associated with higher
carotid IMT in non-diabetics. Increased blood pressure
was significantly associated with a higher risk of carotid
plaques and the exacerbation of all parameters of SCA
in non-diabetics. However, increased blood pressure was
only significantly associated with higher baPWV among
all MS components and no components of MS affected
other SCA parameters in diabetics (Table 2).Relationship between the number of MS components and
SCA parameters according to diabetes status
The number of MS components was significantly corre-
lated with baPWV and carotid IMT in non-diabetics
Figure 1 Comparison of SCA parameters according to the presence of MS and diabetes. (a) baPWV, (b) carotid IMT. DM, diabetes mellitus.
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p < 0.001). However, it was not significantly correlated
with either in diabetics (baPWV: r = 0.022, p = 0.660;
carotid IMT: r = −0.003, p = 0.958) (Figure 2).Impact of MS and diabetes on SCA parameters
Multiple linear regression analysis for baPWV and ca-
rotid IMT was performed using age, gender, smoking
status, BMI, LDL, MS, and diabetes (Table 3). The results
showed that age (β = 14.516, p < 0.001), male sex (β =
52.753, p < 0.001), MS (β = 87.450, p < 0.001), and diabetes
(β = 87.408, p < 0.001) were significantly associated with
baPWV. Meanwhile, age (β = 0.010, p < 0.001), male sex
(β = 0.057, p = 0.001), LDL cholesterol (β = 0.001, p <
0.001), MS (β = 0.042, p < 0.001), and diabetes (β = 0.031,
p = 0.005) were significantly associated with carotid IMT.
Multiple logistic regression analysis was performed for ca-
rotid plaques using the same covariates (Table 3). The re-
sults showed that age (odds ratio [OR], 1.08; 95%
confidence interval [CI], 1.07–1.10; p < 0.001), male sex
(OR, 1.36; 95% CI, 1.00–1.85; p = 0.050), MS (OR, 1.26;
95% CI, 1.01–1.57; p = 0.041), and diabetes (OR, 1.50; 95%
CI, 1.17–1.93; p = 0.002) were significantly associated with
the prevalence of carotid plaques.Discussion
To the best of our knowledge, the present study provides
the first information on the differential impact of MS on
atherosclerotic changes according to diabetes status. The
AHA/NHLBI criteria were chosen because they are
easy to apply to clinical and epidemiological studies,
clearly define each MS component regarding medica-
tion status, and follow the current criteria of impaired
fasting glucose [12].Several previous studies assessed the association
between MS and atherosclerosis. In the Baltimore Longi-
tudinal Study of Aging (BLSA), Scuteri et al. [13] found
that subjects with MS have significantly greater carotid
IMT and stiffness than subjects without MS. Nakanish
et al. [14] found that clustered features of MS are closely
related to the risk of increased aortic PWV in middle-
aged Japanese men. However, these studies raised
substantial concerns about age-associated increases in
vascular stiffness and thickness. Furthermore, they did
not consider that MS was not a clinical diagnosis but ra-
ther a pre-morbid condition for the development of
diabetes, which is closely associated with atherosclerosis.
The present study revealed that subjects with MS had
greater baPWV, carotid IMT, and plaques than those
without MS among non-diabetics. However, this impact
of MS on SCA was not observed in subjects with estab-
lish diabetes, although both MS and diabetes were inde-
pendently associated with all vascular parameters after
considering risk factors. In addition, the number of MS
components was significantly associated with increases
in vascular stiffness and thickness in only non-diabetics.
Considering the differential impact of MS on SCA
according to the presence of diabetes, it might be im-
portant to identify the presence of MS in non-diabetic
individuals. However, a concurrent diagnosis of MS in
individuals with established diabetes might be of little
value for the risk stratification of CVD.
The present study identified different impacts of the
individual components of MS on SCA, including vascu-
lar stiffness and thickness, according to diabetes status.
Vascular stiffness reflected by baPWV was influenced by
several MS components in non-diabetics, including in-
creased blood pressure, triglyceride, and fasting glucose
as well as decreased HDL. However, only increased
Table 2 Parameters of SCA according to the presence of MS components in both non-diabetics and diabetics
Characteristic n baPWV (cm/s) Carotid IMT (mm) Carotid plaques OR (95% CI)
No diabetes
Increased waist circumference
No 1020 1471 ± 8 0.74 ± 0.01 1.00
Yes 1129 1482 ± 7 0.78 ± 0.01 * 0.96 (0.73–1.27)
Increased blood pressure
No 1008 1393 ± 7 0.73 ± 0.01 1.00
Yes 1131 1550 ± 6 * 0.78 ± 0.01 * 2.03 (1.59–2.59) *
Increased triglycerides
No 1584 1458 ± 5 0.76 ± 0.01 1.00
Yes 565 1528 ± 9 * 0.76 ± 0.01 0.97 (0.76–1.24)
Decreased HDL
No 1504 1467 ± 6 0.75 ± 0.01 1.00
Yes 645 1497 ± 9 † 0.78 ± 0.01 * 1.15 (0.92–1.45)
Increased fasting glucose
No 1523 1467 ± 6 0.76 ± 0.01 1.00
Yes 626 1500 ± 9 † 0.76 ± 0.01 1.10 (0.87–1.40)
Type 2 diabetes
Increased waist circumference
No 145 1657 ± 26 0.84 ± 0.02 1.00
Yes 266 1632 ± 18 0.84 ± 0.02 0.81 (0.47–1.41)
Increased blood pressure
No 95 1534 ± 27 0.81 ± 0.03 1.00
Yes 316 1673 ± 14 * 0.84 ± 0.01 1.16 (0.70–1.95)
Increased triglycerides
No 282 1637 ± 16 0.83 ± 0.02 1.00
Yes 129 1650 ± 23 0.85 ± 0.02 1.04 (0.65–1.65)
Decreased HDL
No 264 1649 ± 16 0.84 ± 0.02 1.00
Yes 147 1627 ± 22 0.84 ± 0.02 1.06 (0.68–1.66)
Data are expressed as mean ± SD. All models are adjusted for age, gender, smoking status, LDL, and BMI. baPWV, brachial–ankle pulse wave velocity; HDL,
high-density lipoprotein; IMT, intima–medial thickness; LDL, low-density lipoprotein. *p < 0.001; †p < 0.01; ‡p < 0.05.
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This might be closely associated with the concrete
relationship between baPWV and blood pressure irre-
spective of diabetes status. On the contrary, vascular
thickness reflected in carotid IMT and plaque was
influenced by MS components, including increased waist
circumference and blood pressure, and decreased HDL;
however, no MS components significantly affected vas-
cular thickness in diabetics. These results suggest that
the progression of atherosclerosis might be directly
dependent upon hyperglycemia in patients with es-
tablished diabetes status [15,16] but might be influenced
by multiple CV risk factors, especially the component of
increased blood pressure [17], in patients with a status
of MS without diabetes.MS has recently been promoted as a means of identify-
ing the risk of diabetes development. Gupta et al. [18]
found that both impaired fasting glucose and MS can pre-
dict the risk of new-onset diabetes and that MS is a better
predictor of the risk of new-onset diabetes in hypertensive
patients. In contrast, Stern et al. [19] reported that MS is
inferior to the Framingham Risk Score, an established pre-
dictive model for either type 2 diabetes or CVD. In the
present study, although we did not analyze the significance
of MS as a predictor of type 2 diabetes development,
diabetics had a significantly greater risk of SCA than non-
diabetics, independent of MS status. These results suggest
that diabetes strongly influences atherosclerosis independ-
ent of MS and highlight importance of identifying the new
development of diabetes in non-diabetics with MS.
Figure 2 Correlations between the number of MS components, and baPWV and carotid IMT. (a) Non-diabetics, (b) diabetics.
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65–85% of diabetic individuals have MS [20-22]. How-
ever, only a few studies have examined the effect of the
combination of MS and diabetes on the risk of CVD,
and their results are inconsistent. Malik et al. [23]
showed that individuals with MS but not diabetes haveTable 3 Multiple linear logistic regression analysis of the dete
baPWV Carotid
β SE p β
Age 14.516 0.569 <0.001 0.010
Sex (male) 52.753 14.365 <0.001 0.057
Smoking −8.674 15.121 0.571 −0.013
BMI 2.933 1.603 0.067 0.002
LDL 0.257 0.136 0.059 0.001
MS 87.450 10.394 <0.001 0.042
Diabetes 87.408 12.802 <0.001 0.031
baPWV, brachial–ankle pulse wave velocity; BMI, body mass index; IMT, intima–medincreased risks of CHD and CVD, and that diabetes pre-
dicts CHD, CVD, and overall mortality. Alexander et al.
[21] reported that the prevalence of CHD is substantially
higher in subjects with both diabetes and MS than in
those with only diabetes. Tong et al. [22] showed that
the presence of MS is associated with an increased riskrminants of baPWV, and carotid IMT and plaques
IMT Carotid plaques
SE p OR (95% CI) p
0.001 <0.001 1.08 (1.07–1.10) <0.001
0.013 <0.001 1.36 (1.00–1.85) 0.050
0.013 0.307 1.37 (0.99–1.88) 0.054
0.001 0.199 0.99 (0.96–1.03) 0.576
0.001 <0.001 1.00 (0.99–1.00) 0.786
0.009 <0.001 1.26 (1.01–1.57) 0.041
0.011 0.005 1.50 (1.17–1.93) 0.002
ial thickness; LDL, low-density lipoprotein; MS, metabolic syndrome.
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contrary, Church et al. [24] reported that the presence of
diabetes is associated with a 3-fold greater CVD mortal-
ity risk and that MS status does not affect this risk in
men from the Aerobics Center Longitudinal Study
(ACLS). In addition, while MS and diabetes confer an in-
creased risk of CVD, recent evidence suggests that sub-
jects with these conditions have a wide range of
increased risks [25-27]. Malik et al. [26] reported that
subjects with MS or diabetes have low risks of CHD
when carotid IMT or coronary artery calcium (CAC) is
not elevated. Furthermore, they reported that CAC pre-
dicts CVD and CHD events better than carotid IMT.
Wong et al. [27] reported that subjects with MS and dia-
betes have a greater incidence and progression of
CAC than those without these conditions; moreover,
progression also predicts CHD events in those with
MS and diabetes. The evaluation of baPWV and ca-
rotid IMT in the present study might be insufficient
to stratify the CV risk in diabetic individuals because
these SCA markers were not significantly different be-
tween diabetics with and without MS. Therefore, fur-
ther investigations might be required for complete
CV risk stratification and should include the assess-
ment of morphological and functional vascular dam-
age as well as serological markers in patients with
MS and diabetes.
MS is a pre-morbid condition rather than a clinical
diagnosis and has been advocated as a useful clinical tool
for predicting diabetes and CVD. Although a number of
different definitions of MS include diabetes as a diagnos-
tic criterion of MS, the World Health Organization
(WHO) strongly recommended that the conditions of
established diabetes or CVD should be excluded in the
definition of MS and proposed research that justifies the
inclusion of type 2 diabetes in the definition [7]. Given
the current controversy over the definition of the MS,
the present result that diabetes strongly influences SCA
irrespective of the presence of MS is good evidence ar-
guing against the inclusion of patients with established
type 2 diabetes in the domain of MS.
This study has some limitations. First, the criteria of
MS might be dependent on race and ethnicity [28].
However, the present study included only a Korean
population. Second, the impact of MS on the progres-
sion of atherosclerosis might somewhat differ according
to age group [29]. However, no sub-analysis of SCA
according to age group was not performed because the
participants of this study were relatively older. Third, a
previous study reported that dynamic endurance training
favorably affects most of the CV risk factors related to
MS [30]. However, we did not evaluate the physical
activity of participants. Fourth, there were relatively
few subjects with diabetes compared to those withoutdiabetes because our study was a community-based
cohort study. Fifth, we could not eliminate the pos-
sible effects of underlying disease and medication for
hypertension, dyslipidemia, and diabetes on atheroscler-
osis because of the observational design of this study.
Finally, we did not evaluate the degree of hyperglycemic
control using HbA1c in diabetic patients. Further pro-
spective studies with larger sample sizes are required to
address these issues.
Conclusions
In conclusion, MS has an incremental impact on SCA in
conditions without diabetes. The identification of MS
and its individual components is more important for the
risk stratification of CVD in non-diabetic individuals.
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